Winning the Irish Healthcare Awards 2024, a research project paper unveiled the first Irish data on the effect of HPV vaccination on cervical cancer. This groundbreaking study will have a significant impact on cervical screening practices in Ireland and contribute to the global fight against cervical cancer.

The National Screening Service places a strong emphasis on research, viewing it as a crucial component of their strategic focus and an essential part of Ireland's Cervical Cancer Elimination plan. The recognition at the Irish Healthcare Awards highlights the importance of this study in shaping the future of cervical screening both locally and internationally.

Published in the Irish Journal of Medical Science, the paper titled 'The effect of HPV vaccination on the rate of high-grade cytology in 25-year-old women attending cervical screening in Ireland' revealed a decrease in the percentage of high-grade precancer cells in cervical screening tests of 25-year-old women. This early indication showcases the potential protective benefits of HPV vaccination in preventing cervical cancer.

Utilizing population data from CervicalCheck and the National Immunisation Office, the National Screening Service collaborated across teams to conduct this research. With more vaccinated women becoming eligible for CervicalCheck, researchers anticipate a continued decline in precancerous cell changes among young women. This study serves as a valuable resource for guiding future service development and planning in cervical screening.

Continuing their commitment to research, the National Screening Service will persist in conducting and commissioning studies, evaluating evidence, and engaging with policymakers to advocate for effective population screening practices.